Endochlastic DNA: Potential Drug Targets and Biomarkers (G11319)

Target Name: ECD

NCBI ID: G11319

Content of Review Report on ECD Target / Biomarker

ECD

Endochlastic DNA: Potential Drug Targets and Biomarkers

ECD ( short for Endochlastic DNA), also known as SGT1, is a protein that is expressed in most tissues of the body. It is a key regulator of cell division and is involved in the process of cell growth and differentiation. ECD has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, ECD has become a focus of interest for researchers looking for new drug targets or biomarkers.

One of the key features of ECD is its ability to interact with other proteins. This interaction allows ECD to regulate the activity of other proteins, which can lead to the regulation of cellular processes such as cell growth, differentiation, and apoptosis. One of the well-known interactions of ECD is with the protein p53, which is a key regulator of DNA damage repair.

Research has shown that ECD plays a role in the regulation of p53 function. p53 is a protein that is known for its ability to repair damaged DNA, and is a key regulator of the cell's response to DNA damage. Studies have shown that ECD can interact with p53 and regulate its activity. This interaction between ECD and p53 suggests that ECD may be a useful drug target or biomarker for the treatment of p53-related diseases.

Another potential application of ECD is its role in the regulation of cell cycle progression. The cell cycle is the process by which a cell grows and replicates its genetic material. ECD is involved in regulating the length of the cell cycle and in the process of cell division. Studies have shown that ECD plays a role in regulating the length of the cell cycle and in the process of mitosis. This suggests that ECD may be a useful drug target or biomarker for the treatment of conditions related to the cell cycle, such as cancer.

In addition to its role in cell division, ECD is also involved in the regulation of cellular signaling pathways. ECD has been shown to interact with various signaling pathways, including the TGF-β pathway. This interaction suggests that ECD may be a useful drug target or biomarker for the treatment of conditions related to TGF-β signaling, such as cancer.

ECD has also been shown to play a role in the regulation of cellular adhesion. Adhesion is the process by which cells stick together to form tissues and organs. ECD is involved in regulating the stickiness of cells to the surface of the cell, which is a key step in the process of adhesion. This suggests that ECD may be a useful drug target or biomarker for the treatment of conditions related to cellular adhesion, such as cancer.

In conclusion, ECD is a protein that is expressed in most tissues of the body and is involved in the regulation of cell division, the cell cycle, cellular signaling pathways, and cellular adhesion. Its interaction with the protein p53 and various signaling pathways suggests that ECD may be a useful drug target or biomarker for the treatment of p53-related diseases, cancer, TGF-β signaling and cellular adhesion related diseases. Further research is needed to fully understand the role of ECD in disease progression and the development of new treatments.

Protein Name: Ecdysoneless Cell Cycle Regulator

Functions: Regulator of p53/TP53 stability and function. Inhibits MDM2-mediated degradation of p53/TP53 possibly by cooperating in part with TXNIP (PubMed:16849563, PubMed:23880345). May be involved transcriptional regulation. In vitro has intrinsic transactivation activity enhanced by EP300. May be a transcriptional activator required for the expression of glycolytic genes (PubMed:19919181, PubMed:9928932). Involved in regulation of cell cycle progression. Proposed to disrupt Rb-E2F binding leading to transcriptional activation of E2F proteins (PubMed:19640839). The cell cycle -regulating function may depend on its RUVBL1-mediated association with the R2TP complex (PubMed:26711270). May play a role in regulation of pre-mRNA splicing (PubMed:24722212)

The "ECD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets